Transgene: Peer-Reviewed Publications Confirm the Potential of Transgene’s TG4001 and TG6002


STRASBOURG, France–(BUSINESS WIRE)–#TG4001–Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, announces the publication of two articles highlighting the potential of TG4001 and TG6002, two clinical-stage products, that are expected to generate new clinical data in H2 2019. TG4001 in Gynecologic Oncology   The data confirm the potential of TG4001 (Tipapkinogen Sovacivec), administered as a monotherapy, to…..